Overview

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine Efficacy, Safety and Tolerability of MDX-010 (BMS-734016) administered with or without Prophylactic Oral Budesonide.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Medarex
Treatments:
Antibodies, Monoclonal
Budesonide
Ipilimumab